Jason Hawkes, MD, MS, provided an in-depth look at the potential role of dupilumab (Dupixent; Sanofi and Regeneron ...

Madison, a twelve-year-old from Illinois, visits a medical clinic every other week to get injections of Xolair, a powerful ...

Blue Cross Blue Shield just made it harder for many patients to get vital asthma and allergy medications — all while ...

RHHBY records impressive first-quarter 2025 performance on the back of strong demand for key drugs. The company confirms 2025 ...

Investing.com -- Roche on Thursday reported a 6% increase in group sales for the first quarter of 2025, driven by strong ...

Swiss drugmaker Roche said on Thursday its first-quarter sales rose a forecast-beating 7% driven by breast cancer drug Phesgo ...

( NewsNation) — The life of 12-year-old Maddie Krelle, who has life-threatening food allergies and severe asthma, depends on ...

Celldex’s cash runway extends into 2027, but potential delays or hurdles could necessitate earlier fundraising, exerting ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

Blue Cross Blue Shield mandates severe asthma patients self-administer drugs at home, unless their provider gets prior approval from the company.

Blue Cross is requiring at-home injection for severe asthma drugs in five states, raising concerns among doctors and patients ...

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...